TP53 and B-cell chronic lymphocytic leukemia: The first published study reporting resistance among CLL patients treated with acalabrutinib identified 2 patients, one of whom developed resistant disease with a mutation in BTK, the other who developed a Richter’s transformation with a mutation in BTK and a dominant TP53-mutated clone[47].